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Abstract of thesis 
In this dissertation, the author describes the functional consequences of abnormalities of Mafb gene, multiple 
missense mutations in which are identified in a rare congenital disease, multicentric carpal tarsal osteolysis (MCTO). 
The summary is as follows: 
Backgrounds and purpose: 
MCTO is a rare skeletal disease with progressive osteolysis at the carpal and tarsal bones. Autosomal missense 
mutations in the transactivation domain of transcription factor MAFB are known to cause MCTO. Because the 
transcription factor MafB is highly expressed in osteoclasts, it was hypothesized that the missense mutations in MAFB 
promotes osteoclastogenesis in MCTO. Wild-type MafB was reported to negatively regulate osteoclastogenesis in 
vitro. In addition, missense mutation was shown to decrease the transactivation function of MafB. From these findings, 
it was previously hypothesized that the mutant MafB protein loses its original function and causes upregulation of 
osteoclast differentiation in MCTO. However, the function of MafB in osteoclastogenesis in vivo and its relation to 
MCTO has not been experimentally demonstrated. Based on these backgrounds, the author aims at clarifying the 
function of MafB in osteoclast differentiation and its relevance to MCTO using mouse models. 
Materials and Methods:  
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 Myeloid specific Mafb knock-out mice (Mafbf/f::LysM-Cre) were used in this study to examine the function of 
MafB in osteoclasts. The effect of osteoclatogenesis against the bone phenotypes of these mice were examined by 
measuring the bone density of Mafbf/f::LysM-Cre mice at 8 weeks using micro-CT analysis. In addition, resistance 
against age-related osteoporosis and RANKL-induced bone loss was also analyzed using micro-CT analysis. 
Osteoclatogenesis ability of the bone marrow cells of Mafbf/f::LysM-Cre mice was measured by primary osteoclast 
differentiation assay and pit assay. Moreover, RNA-sequencing was conducted to analyze the candidate pathways 
that MafB could be regulating during osteoclast differentiation. Following these findings, mouse harboring the human 
MCTO mutation (MafbMCTO/MCTO) was generated using the CRISPR-Cas9 system to relate the author’s findings from 
Mafbf/f::LysM-Cre mice to the pathophysiology of MCTO. Bone phenotype of femurs and tarsal bones was analyzed 
through micro-CT. To analyze the effect of MCTO on the MafB protein itself, transactivation level of MCTO mutated 
MafB was measured using luciferase assay against known MafB target promoters. Finally, MCTO mutation was 
related to osteoclastogenesis ability of MafbMCTO/MCTO mice, by primary osteoclast differentiation assay using bone 
marrow cells of MafbMCTO/MCTO mice. 
Results:  
The author first conducted a micro-CT analysis of the femur bone of Mafbf/f::LysM-Cre mice, finding an increase 
in bone density compared to control, and thus, he hypothesized that MafB promotes osteoclast differentiation in vivo. 
This was further confirmed by Mafbf/f::LysM-Cre mice exhibiting resistance against osteoclast driven bone resorption. 
Culturing osteoclasts from bone marrow cells of Mafbf/f::LysM-Cre mice showed lower numbers of multinucleated 
cells compared to control, especially at 42 hours after RANKL-induction. To identify the pathway that MafB 
regulates in osteoclastogesis, RNA-sequencing was performed against Mafbf/f::LysM-Cre mice derived osteoclasts 
at 42 hours after RANKL-induction. Osteoclast inhibitory genes and markers of other immune cells including 
macrophages, were up-regulated in Mafbf/f::LysM-Cre mice derived osteoclasts. From this, it was predicted that 
MafB physiologically promotes osteolastogenesis by fine tuning osteoclast precursors to the osteoclast linage.  
However, the results obtained from Mafbf/f::LysM-Cre mice contradicted to the symptoms of MCTO patients if 
the MCTO-related MAFB missense mutations result in loss-of-function. Therefore, the bone phenotypes of 
MafbMCTO/MCTO mice were analysed though micro-CT. The bone density of femur bones and tarsal bone volume was 
comparable between control and MafbMCTO/MCTO mice at 2 weeks. However, both femur bone density and tarsal bone 
volume were significantly lower in MafbMCTO/MCTO mice by 8 weeks. The function of MCTO mutated MafB were 
also examined by luciferase assay against reported target genes of MafB, where MCTO mutated MafB increased 
transcriptional ability compared to MafB containing the intact protein sequence. From the in vivo phenotype of 
MafbMCTO/MCTO mice, it was suggested MafbMCTO/MCTO mice increases osteoclast differentiation. Therefore, osteoclast 
differentiation was assessed using primary osteoclast differentiation assay using MafbMCTO/MCTO mice derived cells. 
As a result, MafbMCTO/MCTO mice showed increased multinucleated cell number compared to control, suggesting that 
MCTO occurs from hyper-differentiation of osteoclasts. 
Discussion: 
In this study, the author evaluated the function of MafB in osteoclastogenesis in vivo for the first time. The results 
indicated that MafB promotes the differentiation of osteoclasts and that the MCTO mutation activates transcriptional 
function of MafB. Therefore, the author hypothesized that MCTO is caused by over-differentiating osteoclasts. These 
 were shown by Mafbf/f::LysM-Cre mice being resistance against osteoclast driven bone resorption and primary 
osteoclast differentiation experiments showing lower multinucleated osteoclasts. RNA sequencing suggested that 
MafB regulates osteoclastogenesis at later stages of differentiation by priming osteoclast progenitors to the osteoclast 
linage. This study demonstrated that wild-type MafB positively regulates osteoclastogenesis at later stages, although 
previous studies suggested that MafB worked as a negative regulator against osteoclastogenesis. 
It was thus predicted that the MCTO missense mutations upregulate the MafB function. The in vivo bone 
phenotypes of MafbMCTO/MCTO mice presented osteolysis-like phenotype. The transactivation function of MafB was 
shown to be increased in MCTO-mutated MafB. Primary osteoclast differentiation assay using MafbMCTO/MCTO mice-
derived cells supported this hypothesis, where multinucleated osteoclast number were increased in cultures of 
MafbMCTO/MCTO mice derived cells. These results suggest that MCTO is caused by increased MafB function, which 
abnormally activate osteoclast function.  
Despite these findings, possibilities of alternative causes unrelated to osteoclastgenesis still remain. More 
investigation through histological examination and rescue experiment using bisphosphonate at the timing of onset 
must be conducted to truly validate the author’s hypothesis. 
 
 Abstract of assessment result 
 
【Review】 
The present study demonstrated that wild-type MafB promotes osteoclastogenesis and that the missense 
mutations in MAFB gene indeed cause MCTO by enhancing osteoclast differentiation through conferrinig an increase 
upon the MafB function, through animal models. In this regard, this work is highly valuable not only for our better 
understanding of pathophysiology of a rare disease, MCTO, but also for potentially facilitating the drug development 
for MCTO patients. This paper deserves the credit for PhD in medical sciences. 
 
【Result】 
The final examination committee conducted a meeting as a final examination on 22/01/2019. The applicant 
provided an overview of dissertation, addressed questions and comments raised during Q&A session. All of the 
committee members reached a final decision that the applicant has passed the final examination. 
 
【Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be awarded a Doctor of 
Philosophy in Human Biology. 
 
